Is AI Actually Reducing the Cost of Drug Development?

Reflections from our recent forum on AI’s Role in Drug Development Costs: Reverse or Reinforce?

At a recent forum we hosted bringing together leaders across drug discovery, clinical development, and technical operations, one question anchored the entire conversation: Is AI reducing the cost and time of bringing drugs to market?

The answer, as expected, was neither a confident yes nor a dismissive no. It was far more nuanced, and went into themes we weren’t expecting.

The Iceberg Nobody Wants to Talk About

One of the most resonant observations from the evening was this: the industry keeps layering AI on top of broken foundations.

We invest in shiny new tools. We add AI pipelines. But underneath? Data that isn't standardized. Molecule names that change at every handoff from research to development to regulatory without anyone tracking the aliases. Batch records still arriving as handwritten PDFs from contract research organizations in different languages.

As one panelist put it, if you can't ask a basic question like "what have we tried with this molecule?" and get a reliable and comprehensive answer, then training an AI to answer it for you doesn't solve the problem. It decorates it.

The foundational work, naming conventions, data lineage, structured capture at the point of generation, is unglamorous. It doesn't make a good conference slide. But it remains the single biggest limiting factor on what AI can actually deliver.

Where the Real Money Goes

The forum drew a clear distinction between where AI excitement is concentrated (preclinical, roughly one-third of capitalized drug development costs) and where the real burn happens (clinical trials, the other two-thirds).

The two biggest cost drivers in clinical development identified by the group:

1. Protocol amendments. A single amendment on a Phase III trial can cost upwards of $500,000. When companies optimize for milestone checkboxes, first patient in, protocol finalization, rather than downstream outcomes, they invite amendments. AI's value here isn't in speed; it's in simulation and scenario planning before the protocol is locked.

2. Patient recruitment and retention. Consistently the number one cause of trial delays. Smarter trial design, better inclusion/exclusion criteria, more accurate patient matching, earlier integration of real-world data, is where AI can have genuine upstream impact.

The insight that tied these together: speeding up a doomed trial just helps you lose money faster. AI should be the sounding board that prevents you from committing to the wrong trial design in the first place, not just the engine that executes it more efficiently once you have.

The "Go Faster, Do More" Trap

One of the more provocative moments in the evening came when the question of FTE productivity was raised directly. If AI saves your team 30% of their time, what happens to that 30%?

The honest answer from the group: it probably gets filled with more work.

Drug development organizations are not structured to bank efficiency gains. If timelines shrink from twelve years to six, companies are unlikely to sustain smaller teams, they'll take on more molecules, more indications, more parallel workstreams. The overall cost may not fall at all. It may just produce more output.

There's also an overlooked underlying risk here: cognitive overload. AI tools that produce five-paragraph answers to two-sentence questions, or that flood teams with AI-generated infographics after every meeting, can increase cognitive burden rather than reduce it. The metric that no one has yet figured out how to measure, cognitive load reduction, may actually be one of the more meaningful ones.

Measuring What Actually Matters

The forum surfaced a critical gap: most organizations aren't measuring AI impact rigorously, and those that try often pick the wrong metrics.

The most credible framework discussed was counterfactual: if we didn't use AI for this, what would the alternative have cost? For decisions that have to be made regardless, what molecule to progress, what assay to run, you can benchmark the AI-assisted path against the market price of the alternative. That gives you a real number.

On the research side, hit rate improvement is measurable and meaningful, if AI-guided selection increases your screening hit rate from 2% to 20%, that's a concrete, auditable claim. But the group was clear: replicate it on your own internal data before you trust a paper's numbers. Benchmark everything. Trust, but verify.

What AI Is Actually Good For Right Now

Cutting through the hype, the forum landed on a pragmatic set of near-term applications where AI adds genuine, demonstrable value:

- Simulation and scenario planning for trial design - modeling trade-offs between endpoints, patient populations, and timelines before committing

- Unstructured data processing- extracting signal from EHRs, medical notes, and external documents that would otherwise require significant manual effort

- Knowledge management- making decades of institutional experience searchable and accessible, preventing the constant reinvention of solved problems

- Reducing white space between development phases- AI-assisted drafts, parallel workstreams, real-time data cleaning

What it is not yet: a replacement for gold-standard clinical evidence, a reliable autonomous decision-maker, or a shortcut past the hard work of data infrastructure.

The Closing Thought

The forum ended with a reminder worth sitting with: today is the worst AI any of us will ever work with. The trajectory is clear. But the organizations that will capture the most value from that trajectory aren't necessarily the ones moving fastest, they're the ones building the right foundations now, measuring honestly, and resisting the temptation to automate processes that were broken to begin with.

The question isn't whether AI will transform drug development. It will. The question is whether we're solving the right problems with it.

This article is drawn from a forum discussion we hosted with 140+ senior practitioners across biopharma R&D, clinical development, and data science. We hold these events to advance honest, evidence-grounded conversation about technology's role in the industry. If you'd like to be part of future gatherings, follow along or reach out directly.

Visit https://www.datadrivenpharma.com/ for more information on our upcoming conferences and forums.

Upcoming conference- DataDrivenPharmaWest 2026, October 15-16, South San Francisco

Pre-register now to avail exciting discounts and offers.